田欣欣 博士

抗体中心主任

Director of Antibody Research Center  

Phone： 010-80726688-8332

E-mail：tianxinxin@nibs.ac.cn

中心主任简介：

教育经历Education

2019 北京大学、清华大学和北京生命科学研究所联合培养博士研究生项目 生物化学与分子生物学 博士学位

Ph.D. Biochemistry and Molecular Biology, Peking University-Tsinghua University-National Institute Biological Sciences (PTN) Joint Graduate Program, China

2013 北京化工大学 制药工程 学士学位

B.S. Pharmaceutical Engineering, Beijing University of Chemical Technology, China

工作经历 Professional Experience

2023- 北京生命科学研究所 抗体中心主任

Director of Antibody Research Center, National Institute of Biological Sciences, Beijing

2019-2023 北京生命科学研究所 博士后

Postdoctoral Fellow, National Institute of Biological Sciences, Beijing

发表文章 Publications（* co-first author）

1. Wei X, Zhao L, Yang F, Yang Y, Zhang H, Du K, Tian X, Fan R, Si G, Wang K, Li Y, Wei Z, He M, Sui J. A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion. Molecular Therapy. 2024 Sep 7.

2. Tian X*, Liu X*, Ding J, Wang F, Wang K, Liu J, Wei Z, Hao X, Li Y, Wei X, Zhang H, Sui J. An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice. Nature Biomedical Engineering. 2023 Jan;7(1):8-23.

3. Liu X*, Tian X*, Hao X, Zhang H, Wang K, Wei Z, Wei X, Li Y, Sui J. A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering. Molecular Therapy-Oncolytics. 2022 Dec 15;27:256-69.

4. Yang F, Zhao L, Wei Z, Yang Y, Liu J, Li Y, Tian X, Liu X, Lü X, Sui J. A cross-species reactive TIGIT-blocking antibody Fc dependently confers potent antitumor effects. The Journal of Immunology. 2020 Oct 15;205(8):2156-68.

专利 Patent

1. Sui J, Tian X. Anti-CD98 antibodies and uses thereof. Patent No. WO2022252167A1. 2022

抗体中心职能 Antibody Research Center

抗体在生物学和医学研究中发挥着重要作用，既是有效的科研工具，又是成功应用的药物形式。北京生命科学研究所（NIBS）抗体中心（ARC）致力于根据各实验室不同的实验目标，提供多种抗体（包括多克隆抗体、单克隆IgG抗体、IgG变体、多价抗体和纳米抗体）开发和融合蛋白定制服务。
利用小鼠杂交瘤技术和噬菌体展示技术平台，我们已成功开发了来源于不同种属（包括小鼠、人类、羊驼、骆驼和兔子）的工具性抗体和功能性抗体。同时，为了更好地满足各实验室的工作需求和支持NIBS的科研发展，我们一直在积极整合先进的抗体工程策略来拓展抗体中心平台。
抗体相关的研究不仅能有效加强基础科研与临床应用间的联系，还能为疾病机制研究提供独特新视角。抗体中心主要开展用于恶性肿瘤预防、诊断和治疗的新型抗体相关药物研究，积累了大量的实验模型和抗体工具。此外，抗体中心乐于依据其他研究团队的创新基础研究成果，合作开发针对不同疾病的治疗和诊断抗体。
Antibodies play essential roles in biological and medical research, acting as both effective scientific tools and therapeutic agents. The Antibody Research Center (ARC) at NIBS is dedicated to providing a range of services for generating various types of antibodies—including polyclonal antibodies, monoclonal IgG antibodies, IgG variants, multi-valent antibodies, and nanobodies—as well as fusion proteins tailored for diverse experimental goals.
Utilizing mouse hybridoma technology and phage display platforms, we have successfully developed a wide array of tool and functional antibodies from various species, including mouse, human, alpaca, camel, and rabbit. To enhance support for scientific research at NIBS, we are actively expanding our platform by incorporating advanced antibody engineering strategies that address the evolving needs of our laboratories.
Antibody-related research not only strengthens the connection between basic scientific research and clinical applications but also provides new insights into the mechanisms of disease. Regarding research focus, the ARC develops and evaluates innovative antibody-based biologics for the prevention, diagnosis, and treatment of malignant cancers, while acquiring a robust collection of experimental models and antibody tools. Additionally, we are open to collaborating with other research groups to develop therapeutic and diagnostic antibodies for various diseases based on their foundational research findings. Feel free to reach out to our passionate team.